Junzhong Lai, Jiadi Liang, Yong Zhang, Bingchen Zhang, Jianhui Wei, Jiqiang Fan, Linqin Chen, Zhirong Chen, Qiumei Li, Dong Guo, Jizhen Lin, Qi Chen
DNA methyltransferase inhibitors (DNMTis) have found widespread application in the management of cancer. Zebularine (Zeb), functioning as a demethylating agent, has exhibited notable advantages and enhanced therapeutic efficacy in the realm of tumour immunotherapy. Nevertheless, due to its lack of targeted functionality, standalone Zeb therapy necessitates the administration of a substantially higher dosage. In this investigation, we have devised an innovative nanodrug formulation, comprising the DNA methyltransferase inhibitor Zeb and pH-responsive chitosan (CS), hereinafter referred to as CS-Zeb nanoparticles (NPs)...
October 12, 2023: Biomedicine & Pharmacotherapy